PMID- 37761848
OWN - NLM
STAT- MEDLINE
DCOM- 20230929
LR  - 20231003
IS  - 2073-4425 (Electronic)
IS  - 2073-4425 (Linking)
VI  - 14
IP  - 9
DP  - 2023 Aug 28
TI  - The Prediction Analysis of Microarray 50 (PAM50) Gene Expression Classifier 
      Utilized in Indeterminate-Risk Breast Cancer Patients in Hungary: A Consecutive 
      5-Year Experience.
LID - 10.3390/genes14091708 [doi]
LID - 1708
AB  - BACKGROUND: Breast cancer has been categorized into molecular subtypes using 
      immunohistochemical staining (IHC) and fluorescence in situ hybridization (FISH) 
      since the early 2000s. However, recent research suggests that gene expression 
      testing, specifically Prosigna((R)) Prediction Analysis of Microarray 50 (PAM50), 
      provides more accurate classification methods. In this retrospective study, we 
      compared the results of IHC/FISH and PAM50 testing. We also examined the impact 
      of various PAM50 parameters on overall survival (OS) and progression-free 
      survival (PFS). RESULTS: We analyzed 42 unilateral breast cancer samples, with 18 
      classified as luminal A, 10 as luminal B, 8 as Human epidermal growth factor 
      receptor 2 (HER2)-positive, and 6 as basal-like using PAM50. Interestingly, 17 
      out of the 42 samples (40.47%) showed discordant results between 
      histopathological assessment and the PAM50 classifier. While routine IHC/FISH 
      resulted in classification differences for a quarter to a third of samples within 
      each subtype, all basal-like tumors were misclassified. Hormone receptor-positive 
      tumors (hazard rate: 8.7803; p = 0.0085) and patients who had higher 10-year 
      recurrence risk scores (hazard rate: 1.0539; p = 0.0201) had shorter OS and PFS. 
      CONCLUSIONS: Our study supports the existing understanding of molecular subtypes 
      in breast cancer and emphasizes the overlap between clinical characteristics and 
      molecular subtyping. These findings underscore the value of gene expression 
      profiling, such as PAM50, in improving treatment decisions for breast cancer 
      patients.
FAU - Dank, Magdolna
AU  - Dank M
AUID- ORCID: 0000-0002-4694-3624
AD  - Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis 
      University, H-1083 Budapest, Hungary.
FAU - Muhl, Dorottya
AU  - Muhl D
AD  - Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis 
      University, H-1083 Budapest, Hungary.
FAU - Polhos, Annamaria
AU  - Polhos A
AD  - Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis 
      University, H-1083 Budapest, Hungary.
FAU - Csanda, Renata
AU  - Csanda R
AD  - Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis 
      University, H-1083 Budapest, Hungary.
FAU - Herold, Magdolna
AU  - Herold M
AUID- ORCID: 0000-0002-1036-6343
AD  - Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis 
      University, H-1083 Budapest, Hungary.
AD  - Department of Internal Medicine and Hematology, Semmelweis University, H-1088 
      Budapest, Hungary.
FAU - Kovacs, Attila Kristof
AU  - Kovacs AK
AD  - Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, 
      H-1091 Budapest, Hungary.
FAU - Madaras, Lilla
AU  - Madaras L
AD  - Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, 
      H-1091 Budapest, Hungary.
FAU - Kulka, Janina
AU  - Kulka J
AD  - Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, 
      H-1091 Budapest, Hungary.
FAU - Palhazy, Timea
AU  - Palhazy T
AD  - Department of Surgery, Transplantation and Gastroenterology, Semmelweis 
      University, H-1082 Budapest, Hungary.
FAU - Tokes, Anna-Maria
AU  - Tokes AM
AD  - Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, 
      H-1091 Budapest, Hungary.
FAU - Toth, Monika
AU  - Toth M
AD  - Department of Radiology, Semmelweis University, H-1082 Budapest, Hungary.
FAU - Ujhelyi, Mihaly
AU  - Ujhelyi M
AUID- ORCID: 0000-0001-7164-563X
AD  - TritonLife Medical Center, H-1135 Budapest, Hungary.
FAU - Szasz, Attila Marcell
AU  - Szasz AM
AUID- ORCID: 0000-0003-2739-4196
AD  - Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis 
      University, H-1083 Budapest, Hungary.
FAU - Herold, Zoltan
AU  - Herold Z
AUID- ORCID: 0000-0001-5990-4889
AD  - Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis 
      University, H-1083 Budapest, Hungary.
LA  - eng
PT  - Journal Article
DEP - 20230828
PL  - Switzerland
TA  - Genes (Basel)
JT  - Genes
JID - 101551097
SB  - IM
MH  - Humans
MH  - Female
MH  - *Breast Neoplasms/genetics
MH  - Hungary
MH  - In Situ Hybridization, Fluorescence
MH  - Retrospective Studies
MH  - Gene Expression
PMC - PMC10530528
OTO - NOTNLM
OT  - PAM50
OT  - breast carcinoma
OT  - gene expression
OT  - immunohistochemistry
OT  - intrinsic subtype
OT  - subtype
COIS- The authors declare no conflict of interest. The funders had no role in the 
      design of the study; in the collection, analyses, or interpretation of data; in 
      the writing of the manuscript; or in the decision to publish the results.
EDAT- 2023/09/28 06:43
MHDA- 2023/09/29 06:44
PMCR- 2023/08/28
CRDT- 2023/09/28 01:15
PHST- 2023/06/26 00:00 [received]
PHST- 2023/08/24 00:00 [revised]
PHST- 2023/08/26 00:00 [accepted]
PHST- 2023/09/29 06:44 [medline]
PHST- 2023/09/28 06:43 [pubmed]
PHST- 2023/09/28 01:15 [entrez]
PHST- 2023/08/28 00:00 [pmc-release]
AID - genes14091708 [pii]
AID - genes-14-01708 [pii]
AID - 10.3390/genes14091708 [doi]
PST - epublish
SO  - Genes (Basel). 2023 Aug 28;14(9):1708. doi: 10.3390/genes14091708.